UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Treasury Stock	Paid-in Capital	Management Notes Receivable	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Equity, beginning balance at Dec. 31, 2017	$ 606,105	$ 0	$ 14	$ 0	$ 617,057	$ (1,116)	$ (9,920)	$ 70
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' contributions	0				425	(425)
Interest on management notes receivable	(78)					(78)
Stock-based incentive compensation	2,139				2,139		0
Net loss	(6,115)						(6,115)
Other comprehensive income (loss)	774							774
Equity, ending balance at Dec. 31, 2018	602,825	0	14	0	619,621	(1,619)	(16,035)	844
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Purchase of BioScrip, Inc.	387,044		4		387,040
Interest on management notes receivable	(62)					(62)
Repayment of management notes receivable	1,310					1,310
Stockholders' redemptions	(2,000)				(2,371)	371
Stock-based incentive compensation	4,170				4,170
Exercise of stock options, vesting of restricted stock, and related tax withholdings	(2,501)			(2,403)	(98)
Net loss	(75,920)						(75,920)
Other comprehensive income (loss)	(8,039)							(8,039)
Equity, ending balance at Dec. 31, 2019	906,827	0	18	(2,403)	1,008,362	0	(91,955)	(7,195)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based incentive compensation	2,920				2,920
Exercise of stock options, vesting of restricted stock, and related tax withholdings	(904)				(904)
Net proceeds from the issuance of common stock	118,934		1		118,933
Cancellation of common stock	0		(1)		1
Net loss	(8,076)						(8,076)
Other comprehensive income (loss)	(3,977)							(3,977)
Equity, ending balance at Dec. 31, 2020	$ 1,015,724	$ 0	$ 18	$ (2,403)	$ 1,129,312	$ 0	$ (100,031)	$ (11,172)